Could a Two-Drug HIV pill work for transgender women?
Disease control
Recruiting now
This study is testing whether switching to a two-drug HIV pill (dolutegravir plus lamivudine) can keep the virus under control in transgender women who are already on a stable three-drug regimen. About 50 participants will take the new pill once daily for 48 weeks. The main goal …
Phase: PHASE4 • Sponsor: UBATEC • Aim: Disease control
Last updated Jun 26, 2026 16:22 UTC